China, IPOs

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX’s door with an IPO application

A month after the Hong Kong Stock Exchange opened its doors to pre-revenue biotechs — and received one guest, Ascletis — Hua Medicine has walked in with its own application to list.

Li Chen

The Shanghai-based diabetes drugmaker is seeking $200 million in the IPO, South China Morning Post reports, although there was no way to confirm the number on the heavily redacted application proof. That would mark a decrease from the $300 million to $400 million that it was previously rumored to be seeking, but it would get Hua through Phase III trials, further R&D and potential launch of its lead drug, dorzagliatin, in China.

Hua bought the drug in 2011, when it first got going, from Roche — for whom founder and CEO Li Chen used to run an R&D center in China. Back then, it was an early-stage candidate. Today, the oral glucokinase activator is in two Phase III studies in China.

Touted as a first-in-class drug, dorzagliatin treats type 2 diabetes by going after the underlying cause: an impaired “glucose sensor.” If you fix the enzyme serving that function, Hua theorizes, you can better regulate the body’s glucose metabolism.

It’s a theory that marquee investors from China and the US alike have bought into. In five financing rounds — capped by a combined Series D and Series E that reaped $117 million just this March — Hua has earned the backing of Arch Venture Partners, Venrock, Eight Roads, F-Prime and WuXi. Prior to the IPO, Arch is the largest shareholder, holding 15% of the shares, followed by Venrock at 12%. Ge Li’s WuXi has almost 9% while his family fund also chipped for 3%.

If all goes according to plan, Phase III results for dorzagliatin both as a monotherapy and in combination with metformin will come out in the second half of 2019, followed by a filing to the CDA (CFDA no more). Hua is aiming for an approval in 2020. In the interim, the 83 staffers — including 59 scientists — will keep themselves busy with more combo trials for the lead drug and some clinical work on a preclinical candidate.

Here’s the breakdown for how they’re going to spend the money:

  • 24% to complete the two Phase III trials for dorzagliatin
  • 14% for further R&D — think combo and differentiation trials — of dorzagliatin
  • 30% for launch and commercialization of dorzagliatin
  • 10% toward mGLUR5, a potential drug candidate for treating dyskinesia induced by Parkinson’s therapy levodopa
  • 12% for additional licensing and partnership opportunities
  • 10% for general and corporate purposes

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->